Pfizer | Intellepedia

Patent and Trademark Dispute Settlements

Exploring successful settlements in IP disputes involving Asian Paints, Colorbar, Pfizer, and their counterparts, showcasing effective dispute resolution outside of court.

Patent Suit over Viagra

Pfizer has sued Watson Laboratories to delay generic Viagra, leveraging the Hatch-Waxman Act and its patents. This case examines Pfizer’s legal strategy and the implications for generic competition in the pharmaceutical market.

Pfizer files for Patent on Known Substance

This post examines Pfizer’s patent application on a known substance and the Indian Patent Office’s refusal in light of Section 3d and the Novartis decision. It discusses whether unpublished patent applications can render a substance as “known” and critiques the merging of novelty and subject matter analysis.

Pfizer falls prey to Section 3(d)

This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence of enhanced efficacy in pharmaceutical patent applications.

Mylan settles Patent Litigation with Pfizer

Mylan has reached a settlement with Pfizer over patent litigation related to Sildenafil, allowing earlier generic market entry in the US. This agreement is expected to lower drug prices and may signal a trend for further settlements involving Indian pharmaceutical companies.